Elevara Medicines

To add a bio or update company history, please click update information.

News from Elevara Medicines

Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis

22 Oct 2025

Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis

Elevara develops oral therapies for rheumatoid arthritis by targeting synovial fibroblasts rather than the immune system, aiming to improve remission rates in chronic inflammatory disease.

Elevara Medicines

Life Sciences
London, United Kingdom
£50m
elevara.com
Update Information

More venture news

Qureight
29 Jul 2026
Qureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Series BLife Sciences
Healome Therapeutics
7 Jul 2026
Healome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
SeedLife Sciences
Revolver Therapeutics
6 Jul 2026
Revolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins
EquityLife Sciences

Elevara Medicines

News from Elevara Medicines

Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis

More venture news

Qureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease

Healome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease

Revolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins